What is Salarius Pharmaceuticals Inc (SLRX)?

Salarius Pharmaceuticals Inc (SLRX) Stock Analysis

$0.840

+0.246 (+29.23%)At close

Loading chart…

High: 0.898
Open: 0.706
VWAP: 0.81
Vol: 6.05M
Mkt Cap: 1.46M
Low: 0.686
Amount: 4.88M
EV/EBITDA, TTM: 0.02

Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.

salariuspharma.com

Valuation Metrics

The current forward P/E ratio for Salarius Pharmaceuticals Inc (SLRX) is -0.00, compared to its 5-year average forward P/E of -0.40.

Forward P/E

Fair

5Y Average P/E

-0.40

Current P/E

-0.00

Overvalued

0.26

Undervalued

-1.06

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.05

Current EV/EBITDA

0.02

Overvalued

0.29

Undervalued

-0.19

Forward P/S

Fair

5Y Average P/S

6.47

Current P/S

0.00

Overvalued

31.44

Undervalued

-18.50

Alphio AI Price Scenarios for SLRX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%SLRX

$0.73

Scenario price

Base

Base · 50%SLRX

$0.67

Scenario price

Bear

Bear · 25%SLRX

$0.60

Scenario price

Events Timeline

2026-01-07 (ET)